{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:59:16Z","timestamp":1791316756675,"version":"4.3.1"},"reference-count":8,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.cllc.2025.02.002","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:13:27Z","timestamp":1739492007000},"page":"267-270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The PESGA Trial: A Prospective, Open-Label, Single-Arm, Phase II Study to Evaluate First Line Therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients, Treated by Induction Carboplatin\/Etoposide\/Pembrolizumab Followed by Maintenance of Pembrolizumab\/ Sacituzumab Govitecan"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8455-9327","authenticated-orcid":false,"given":"Laila C.","family":"Roisman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shir","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afifi","family":"Basel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranin","family":"Marei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belal","family":"Krayim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gleb","family":"Kornev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Asna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Peled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.cllc.2025.02.002_bib0001","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41571-024-00914-x","article-title":"Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer","volume":"21","author":"Sen","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2025.02.002_bib0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"21","key":"10.1016\/j.cllc.2025.02.002_bib0003","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study","volume":"38","author":"Rudin","year":"2020","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.cllc.2025.02.002_bib0004","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1158\/1078-0432.CCR-17-0933","article-title":"Therapy of small cell lung cancer (SCLC) with a topoisomerase-I\u2013inhibiting antibody\u2013Drug conjugate (ADC) targeting trop-2, Sacituzumab Govitecan","volume":"23","author":"Gray","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.cllc.2025.02.002_bib0005","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jtho.2024.09.034","article-title":"OA04.04 Sacituzumab Govitecan as second-line treatment in patients with extensive stage small cell lung cancer","volume":"19","author":"Dowlati","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"26","key":"10.1016\/j.cllc.2025.02.002_bib0006","doi-asserted-by":"crossref","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"issue":"16_suppl","key":"10.1016\/j.cllc.2025.02.002_bib0007","doi-asserted-by":"crossref","first-page":"8592","DOI":"10.1200\/JCO.2024.42.16_suppl.8592","article-title":"Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC) with PD-L1 \u2265 50%: cohort A of EVOKE-02","volume":"42","author":"Patel","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2025.02.002_bib0008","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/bjc.2016.7","article-title":"New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer","volume":"114","author":"Nisman","year":"2016","journal-title":"Br J Cancer"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425000270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425000270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T02:22:41Z","timestamp":1748053361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730425000270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1525730425000270"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2025.02.002","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The PESGA Trial: A Prospective, Open-Label, Single-Arm, Phase II Study to Evaluate First Line Therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients, Treated by Induction Carboplatin\/Etoposide\/Pembrolizumab Followed by Maintenance of Pembrolizumab\/ Sacituzumab Govitecan","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2025.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}